This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-PERMANENT — risk:benefit fails for the canonical archetype.

3-MeO-PCP

PCP RC analog.

Aliases (2)

3-methoxyphencyclidine · 3-MeO-Phencyclidine

TYPICAL DOSE

—

ROUTE

—

CYCLE

—

STORAGE

—

Overview

What is 3-MeO-PCP?

PCP RC analog. Long half-life, high NMDA affinity, frequent association with persistent psychotic episodes in case literature. SKIP-PERMANENT.

What to Expect

Week 1
Tolerability and dose-response.
Week 2-4
Early effect window.
Week 4-8
Peak benefit assessment.
Week 8+
Cycle decision point.

Was this helpful?

Your feedback shapes what we research deeper.

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…

✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸

Loading…

Continue: Extended research →

Our verdict, decision matrix, deep dives, controversies, sources

Related compounds

Cross-referenced from 3-MeO-PCP

Arylcyclohexylamine dissociative anesthetic / non-competitive open-channel NMDA receptor antagonist with sigma-1 agonism, opioid (μ/κ/δ) low-affinity binding, and downstream glutamate-burst → AMPA → BDNF → mTORC1 plasticity cascade

Ketamine analog (deschloro variant). Research chemical dissociative.

Fluorinated ketamine analog. Research chemical dissociative.

Ketamine + PCP hybrid analog. Research chemical dissociative. Originally marketed online 2010-2013 as a "bladder-safe ketamine alternative" — that claim turned out to be false.

Aminoadamantane / Uncompetitive moderate-affinity, voltage-dependent, fast-off-rate NMDA receptor antagonist